Idorsia Pharmaceuticals Ltd has raised a significant sum to cover preparations for the launch of its insomnia drug, daridorexant, and help fund a promising late-stage pipeline.
The Swiss biotech has launched a rights offering that will bring in around CHF575m ($630m) to support the US regulatory filing and, if approved, launch of its insomnia pill, daridorexant
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?